Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ursula Amstutz

Showing results (1-10 of 60) with videos related to

Pageof 6
Sort By:
Medizinische Genetik : Mitteilungsblatt Des Berufsverbandes Medizinische Genetik E.V|July 21, 2025
Preventing adverse drug reactions and more: current clinical use of pharmacogenetic testingUrsula Amstutz
The Lancet. Oncology|October 24, 2018
Genotype-guided fluoropyrimidine dosing: ready for implementationUrsula Amstutz, Carlo R Largiadèr
Pharmacogenomics|May 23, 2018
Come a long way, still a ways to go: from predicting and preventing fluoropyrimidine toxicity to increased efficacy?Seid Hamzic, Ursula Amstutz, Carlo R Largiadèr
Paediatrics & Child Health|November 2, 2012
Using pharmacogenetics to understand adverse drug reactions in childrenKaitlyn Shaw, Ursula Amstutz, Bruce C Carleton
Pharmacogenomics|September 17, 2011
Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicityUrsula Amstutz, Tanja K Froehlich, Carlo R Largiadèr
Scientific Reports|July 2, 2025
Evaluation of variability in cell-free DNA extraction efficiency from plasma and urine and spike-in normalizationFanny Sandberg, Nicholas Kueng, Carlo Rodolfo Largiadèr, et al.
Journal of Experimental & Clinical Cancer Research : CR|October 22, 2008
Hypermethylation of the DPYD promoter region is not a major predictor of severe toxicity in 5-fluorouracil based chemotherapyUrsula Amstutz, Simone Farese, Stefan Aebi, et al.
Pharmacogenomics|June 18, 2009
Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessmentUrsula Amstutz, Simone Farese, Stefan Aebi, et al.
International Journal of Cancer|June 14, 2014
Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicityTanja K Froehlich, Ursula Amstutz, Stefan Aebi, et al.
Frontiers in Pharmacology|June 6, 2022
Clinical Implementation of <i>DPYD</i> Pharmacogenetic Testing to Prevent Early-Onset Fluoropyrimidine-Related Toxicity in Cancer Patients in SwitzerlandUrsina B M Begré, Markus Jörger, Stefan Aebi, et al.
Pageof 6

Showing results (1-10 of 60) with videos related to

Sort By:
Pageof 6
Medizinische Genetik : Mitteilungsblatt Des Berufsverbandes Medizinische Genetik E.V|July 21, 2025
Preventing adverse drug reactions and more: current clinical use of pharmacogenetic testingUrsula Amstutz
The Lancet. Oncology|October 24, 2018
Genotype-guided fluoropyrimidine dosing: ready for implementationUrsula Amstutz, Carlo R Largiadèr
Pharmacogenomics|May 23, 2018
Come a long way, still a ways to go: from predicting and preventing fluoropyrimidine toxicity to increased efficacy?Seid Hamzic, Ursula Amstutz, Carlo R Largiadèr
Paediatrics & Child Health|November 2, 2012
Using pharmacogenetics to understand adverse drug reactions in childrenKaitlyn Shaw, Ursula Amstutz, Bruce C Carleton
Pharmacogenomics|September 17, 2011
Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicityUrsula Amstutz, Tanja K Froehlich, Carlo R Largiadèr
Scientific Reports|July 2, 2025
Evaluation of variability in cell-free DNA extraction efficiency from plasma and urine and spike-in normalizationFanny Sandberg, Nicholas Kueng, Carlo Rodolfo Largiadèr, et al.
Journal of Experimental & Clinical Cancer Research : CR|October 22, 2008
Hypermethylation of the DPYD promoter region is not a major predictor of severe toxicity in 5-fluorouracil based chemotherapyUrsula Amstutz, Simone Farese, Stefan Aebi, et al.
Pharmacogenomics|June 18, 2009
Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessmentUrsula Amstutz, Simone Farese, Stefan Aebi, et al.
International Journal of Cancer|June 14, 2014
Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicityTanja K Froehlich, Ursula Amstutz, Stefan Aebi, et al.
Frontiers in Pharmacology|June 6, 2022
Clinical Implementation of <i>DPYD</i> Pharmacogenetic Testing to Prevent Early-Onset Fluoropyrimidine-Related Toxicity in Cancer Patients in SwitzerlandUrsina B M Begré, Markus Jörger, Stefan Aebi, et al.
Pageof 6